Clinical trials: Visual Pathway Disorder
Brain and Central Nervous System Tumors
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00360854
- Testing
- erlotinib hydrochloride, mutation analysis, polymorphism analysis
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Children's Cancer and Leukaemia Group
Brain and Central Nervous System Tumors, Lymphoma
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00004212
- Testing
- filgrastim, exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children who have relapsed or refractory solid…
- Conditions
- Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma
- Trial name
- NCT00012181
- Testing
- alvocidib, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Bone Marrow Suppression, Brain and Central Nervous System Tumors
Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, etoposide phosphate, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
- Trial name
- NCT00238173
- Testing
- filgrastim, acetylcysteine, carboplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
This phase I trial studies the side effects and best dose of pomalidomide in treating younger patients with tumors of the brain or spine (central nervous system) that have come back or are continuing to grow.
- Conditions
- Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Primary Central Nervous System Neoplasm
- Trial name
- NCT02415153
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide
- Where
- 12 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Primary Central Nervous System Neoplasms
Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- SIOP-LGG-2004 (NCT00276640)
- Testing
- vincristine, carboplatin, vincristine, carboplatin, etoposide, radiation therapy
- Where
- 13 sites in Austria, Belgium and 10 more
- Volunteers
- 3,417 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Phase I trial to study the safety of combining O6-benzylguanine with temozolomide in treating children who have recurrent or refractory brain tumors.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma
- Trial name
- NCT00052780
- Testing
- O6-benzylguanine, temozolomide, filgrastim
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Optic Glioma, Pediatric Brain Tumor, Optic Nerve Glioma
Modified CV Regimen in Optic Pathway Glioma
Optic pathway glioma (OPG) can result in visual deterioration. Symptomatic patients often report deficits in visual acuity (VA), visual field, visual-evoked potentials (VEPs), strabismus, proptosis, disc swelling, and other…
- Trial name
- NCT05278715
- Testing
- Carboplatin, Vincristine, Recombinant human endostatin
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Beijing Sanbo Brain Hospital
Brain and Central Nervous System Tumors, Lymphoma
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT01273090
- Testing
- imetelstat sodium, laboratory biomarker analysis, pharmacological study
- Where
- 23 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00098761
- Testing
- laromustine
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors
Lobradimil and Carboplatin in Treating Children With Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Lobradimil may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the…
- Trial name
- NCT00019422
- Testing
- carboplatin, lobradimil
- Where
- 236 sites in United States, Australia and 5 more
- Sponsor
- National Cancer Institute (NCI)
Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
This randomized phase II trial studies how well low-dose lenalidomide works compared with high-dose lenalidomide in treating younger patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas that have come back…
- Conditions
- Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma
- Trial name
- NCT01553149
- Testing
- Lenalidomide, Pharmacological Study
- Where
- 126 sites in United States, Australia and 2 more
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Premature Birth
A MRI Study of Visual and Motor Pathways in Premature Infants
Approximately 30,000 babies annually are born with extremely low birth weight (ELBW) in the US. These babies often have motor and/or visual problems when they grow up.
- Trial name
- NCT01514747
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00100880
- Testing
- lenalidomide, perfusion-weighted magnetic resonance imaging, diffusion-weighted magnetic resonance imaging
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer, Liver Cancer
- Trial name
- NCT00303940
- Testing
- carboplatin, talabostat mesylate, temozolomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Brain and Central Nervous System Tumors, Neuroblastoma
Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00503724
- Testing
- enzastaurin hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Dyslexia
Validating a Neurocognitive Remediation Model for Visual-Attentional Pathway in Chinese Developmental Dyslexia
Developmental dyslexia is a common and serious specific learning disability affecting up to one in eight children in Hong Kong, with profound consequences for academic success and personal well-being.
- Trial name
- NCT07707700
- Testing
- Action video game intervention group, Active Control (Non-Action Video Game) Group
- Where
- Hong Kong
- Volunteers
- 76 people
- Sponsor
- The Hong Kong Polytechnic University
Brain Tumor, Central Nervous System Tumor
Radiation Therapy in Treating Young Patients With Gliomas
RATIONALE: Specialized radiation therapy that delivers radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00238264
- Testing
- radiation therapy
- Where
- 145 sites in United States, Australia and 4 more
- Volunteers
- 92 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer
- Trial name
- NCT00007813
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00020150
- Testing
- O6-benzylguanine, temozolomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)